The programme started with a preliminary study, published in 2011. Subsequent reports were carried out in three phases. After this, empirical studies were made of the effects of introducing new, innovative medicines in the therapy areas of breast cancer, leukaemia and diabetes, which were presented in five reports.

Following this, a series of reports focusing on policy were published:

The Value of Pharmaceutical Innovation

Researchers: Frank Lichtenberg, Columbia University, and Billie Pettersson, MSD.

The Evaluation and Implementation of New Medicines

With Examples from Cancer Treatment. Researchers: Bengt Jönsson, Stockholm School of Economics, and Nils Wilking, Karolinska Institutet.

Regional Differences in the Use of Medicines

Researchers: Mats Brommels, Johan Hansson, Emma Granström and Emma Wåhlin, Karolinska Institutet.

New Medicines and Medicine-Related Illness

Researchers: Hanna Gyllensten, Nordic School of Public Health, NHV, and Katarina Steen Carlsson, IHE.

Medicines: When is It Reasonable for Individuals to Pay?

Researchers: Per Carlsson and Gustav Tinghög, Linköping University.

The Value of Quality Registers in Health Care

Researchers: Joakim Ramsberg and Martin Neovius, Karolinska Institutet.

The final report, The Value of New Medicines, was presented in November 2013. Researchers: Bengt Jönsson, Stockholm School of Economics, and Katarina Steen Carlsson, IHE.
Research director in charge: Göran Arvidsson.